These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36194956)

  • 21. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors.
    Krall N; Pretto F; Decurtins W; Bernardes GJ; Supuran CT; Neri D
    Angew Chem Int Ed Engl; 2014 Apr; 53(16):4231-5. PubMed ID: 24623670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas.
    Cazzamalli S; Figueras E; Pethő L; Borbély A; Steinkühler C; Neri D; Sewald N
    ACS Omega; 2018 Nov; 3(11):14726-14731. PubMed ID: 30533574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
    Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
    Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustainable water desalination and electricity generation in a separator coupled stacked microbial desalination cell with buffer free electrolyte circulation.
    Chen X; Liang P; Wei Z; Zhang X; Huang X
    Bioresour Technol; 2012 Sep; 119():88-93. PubMed ID: 22728187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species.
    Foti RS; Biswas K; Aral J; Be X; Berry L; Cheng Y; Conner K; Falsey JR; Glaus C; Herberich B; Hickman D; Ikotun T; Li H; Long J; Huang L; Miranda LP; Murray J; Moyer B; Netirojjanakul C; Nixey TE; Sham K; Soto M; Tegley CM; Tran L; Wu B; Yin L; Rock DA
    Drug Metab Dispos; 2019 Oct; 47(10):1111-1121. PubMed ID: 31387871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
    Yang B; Kwon I
    Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing.
    Jäger S; Dickgiesser S; Tonillo J; Hecht S; Kolmar H; Schröter C
    Biol Chem; 2022 Apr; 403(5-6):525-534. PubMed ID: 34535048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
    Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
    PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
    Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
    Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.
    Casi G; Neri D
    J Med Chem; 2015 Nov; 58(22):8751-61. PubMed ID: 26079148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 33. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies.
    Jendryczko K; Rzeszotko J; Krzyscik MA; Kocyła A; Szymczyk J; Otlewski J; Szlachcic A
    Mol Pharm; 2022 May; 19(5):1422-1433. PubMed ID: 35389227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
    Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
    Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.
    Podobnik B; Helk B; Smilović V; Škrajnar Š; Fidler K; Jevševar S; Godwin A; Williams P
    Bioconjug Chem; 2015 Mar; 26(3):452-9. PubMed ID: 25629733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
    Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS
    J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension.
    Li Q; Barrett A; Vijayakrishnan B; Tiberghien A; Beard R; Rickert KW; Allen KL; Christie RJ; Marelli M; Harper J; Howard P; Wu H; Dall'Acqua WF; Tsui P; Gao C; Borrok MJ
    Bioconjug Chem; 2019 Apr; 30(4):1232-1243. PubMed ID: 30912649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.
    Yang Z; Rajendran S; Spires V; Poirson B; Gururajan M; Lin Z; Arbanas J; Krystek S; Loy J; Cheng Y; Carl S; Pace S; Wang Y; Mehl J; Xu S; Vasudevan K; Broz M; Lehman-McKeeman L; Morin P; Graziano RF
    Drug Metab Dispos; 2022 Jul; 50(7):898-908. PubMed ID: 35545256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Automated and enhanced extraction of a small molecule-drug conjugate using an enzyme-inhibitor interaction based SPME tool followed by direct analysis by ESI-MS.
    Ghiasikhou S; Cazzamalli S; Scheuermann J; Neri D; Zenobi R
    Anal Bioanal Chem; 2019 Nov; 411(28):7387-7398. PubMed ID: 31667562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.